Literature DB >> 16060915

The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism.

Omer Ozcan1, Erdinc Cakir, Halil Yaman, Emin Ozgur Akgul, Kivilcim Erturk, Zeynel Beyhan, Cumhur Bilgi, Mehmet Kemal Erbil.   

Abstract

BACKGROUND: The relationship between subclinical hypothyroidism (SH) and cardiovascular disease (CVD) is still under debate. The purpose of the present study was to evaluate plasma total homocysteine (tHcy), high sensitive C-reactive protein (hsCRP), small dense low-density lipoprotein (sdLDL), L-arginine and asymmetric dimethylarginine (ADMA) concentrations and their relationship to nitric oxide (NO) production, measured as plasma nitrite-plus-nitrate (NO(x)) concentration, in patients with SH before and after thyroxine replacement therapy and compared with control group values.
DESIGN: Eighty-four women with SH and 33 healthy women as controls matched to the patient group for sex, age and body mass index (BMI), were enrolled in this study. Lipoprotein profile, tHcy, hsCRP, sdLDL, ADMA, L-arginine and NO(x) were measured in pre- and post-treatment blood samples.
RESULTS: The pretreatment total cholesterol (TC), LDL-C, hsCRP, ADMA and L-arginine levels were significantly higher and NO(x) levels were lower than in the control group. After treatment, hsCRP, ADMA and L-arginine levels were significantly reduced and sdLDL and NO(x) levels were significantly increased.
CONCLUSION: The present study demonstrated an elevation of hsCRP and ADMA plasma levels of patients with SH associated with a reduction in NO production, which may contribute to some cardiovascular alterations. The elevated ADMA and hsCRP levels were reduced after thyroxine replacement. Also the sdLDL levels of SH patients were found to be lower than the control group values whereas TC and LDL were elevated. Even though we found an elevation in sdLDL levels after treatment, those values were still not higher than in the control group.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16060915     DOI: 10.1111/j.1365-2265.2005.02326.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  17 in total

1.  Postprandial lipemia as a risk factor for cardiovascular disease in patients with hypothyroidism.

Authors:  Nedret Tanaci; Derun Taner Ertugrul; Mustafa Sahin; Muammer Yucel; Irem Olcay; Nilgun Guvener Demirag; Alptekin Gursoy
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

2.  Homocysteine levels in Indian women with Polycystic Ovary Syndrome.

Authors:  Mehmet Agilli; Fevzi Nuri Aydin; Tuncer Cayci; Yasemin Gulcan Kurt
Journal:  J Clin Diagn Res       Date:  2014-10-20

3.  Changes in the before and after thyroxine treatment levels of adipose tissue, leptin, and resistin in subclinical hypothyroid patients.

Authors:  Gulhan Akbaba; Dilek Berker; Serhat Isık; Mazhar Muslum Tuna; Suha Koparal; Murat Vural; Fatma Meric Yılmaz; Canan Topcuoglu; Serdar Guler
Journal:  Wien Klin Wochenschr       Date:  2015-09-22       Impact factor: 1.704

4.  Association between plasma homocysteine status and hypothyroidism: a meta-analysis.

Authors:  Yande Zhou; Yufang Chen; Xueqin Cao; Chunfeng Liu; Ying Xie
Journal:  Int J Clin Exp Med       Date:  2014-11-15

5.  Hypothyroidism and cerebral vein thrombosis--a possible association.

Authors:  Ana Rita Peralta; Patrícia Canhão
Journal:  J Neurol       Date:  2008-06-20       Impact factor: 4.849

6.  Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort.

Authors:  Elizabeth N Pearce; Peter W F Wilson; Qiong Yang; Ramachandran S Vasan; Lewis E Braverman
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

7.  Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease.

Authors:  Scott S Billecke; Louis G D'Alecy; Raylene Platel; Steven E Whitesall; Kenneth A Jamerson; Rachel L Perlman; Crystal A Gadegbeku
Journal:  Nephrol Dial Transplant       Date:  2008-09-15       Impact factor: 5.992

8.  Asymmetric dimethylarginine levels in thyroid diseases.

Authors:  E Arikan; C H Karadag; S Guldiken
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

Review 9.  Endogenous nitric oxide synthase inhibitors in the biology of disease: markers, mediators, and regulators?

Authors:  Ben Caplin; James Leiper
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-29       Impact factor: 8.311

10.  IS SALUSIN-ALPHA A NEW MARKER OF CARDIOVASCULAR DISEASE RISK IN HYPOTHYROIDISM?

Authors:  H Usta Atmaca; F Akbas
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Jan-Mar       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.